Headlines

MID WEB AD_Vertical left side 426 pixels (height) x 170 pixels (width).gif

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

In a recent position statement, the International Federation for the Surgery and Other Therapies for Obesity (IFSO) has ‘cautiously’ supported the selective use of ring augmentation (ra) in both primary and revisional metabolic bariatric surgery (MBS), particularly for Roux-en-Y Gastric Bypass (raRYGB). The findings were reported in the paper, ‘Ring-augmented Metabolic Bariatric Surgery Procedures GRADE based International Federation for the Surgery of Obesity and Metabolic

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Bariatric surgery outperforms medical therapy for T2D across income levels

Research

Higher occurrence of marginal ulcers RYGB compared with OAGB

Marginal ulcers (MU) occurred at a relatively high rate after Roux-en-Y gastric bypass (RYGB) compared with one-anastomosis gastric bypass (OAGB), according to a study by researchers from the Kasr Alainy Medical School, Cairo University, Cairo, Egypt. They noted that type 2 diabetes mellitus (T2DM) and the RYGB procedure were significant predictors of MU after adjusting for the confounding factors. The authors noted that despite the success of RYGB, MU has been recognised as

GLP-1 may help alleviate symptoms of anxiety and depression

GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, according to a large register-based study carried out in collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm and Griffith University in Australia. Infographic on anxiety and depression in the UK (Credit: Mark Taylor) "An earlier study examining Swedish registers found the use of GLP-

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

Study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment

A research team affiliated with National Institute of Standards and Technology has made a significant discovery explaining why liver cancers associated with obesity and metabolic disorders tend to be more aggressive and less responsive to conventional treatments. The study reveals that a specific signalling pathway involving endotrophin - a protein secreted during liver fibrosis - and the receptor protein CD44 promotes tumour malignancy and drug resistance. Led by Professor J

New genetic risk score better predicts metabolic conditions

By integrating genetic findings from several of the world's largest biobanks, investigators from Mass General Brigham built metabolic a polygenic risk score (PRS) for predicting obesity and type 2 diabetes (T2D), which capture multiple genetic risk factors to provide an estimate for whether a person may develop a complex medical condition and how they might fare long-term, and outperformed existing disease-prediction models and predicted downstream morbidity and clinical inte

Discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain

A Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment. In one of the largest real-world studies to date examining obesity treatment use and long-term weight changes after GLP-1 discontinuation, researchers at Cleveland Clinic found that many patients s

Olympus launches next-generation VISERA ELITE III surgical imaging platform in US

Olympus Corporation has launched the VISERA ELITE III surgical imaging platform designed to enhance surgical visualization, workflow efficiency and multispecialty flexibility, in the US. The VISERA ELITE III platform is a significant leap forward in surgical imaging and the third major co-developed product by SONY Olympus Medical (SOMED), a joint venture established in 2013. The VISERA ELITE III surgical imaging platform offers advanced features including Yellow Enhancement (

Rise in GLP-1 treatment for bariatric surgery-eligible patients

According to researcher from Ohio State University Wexner Medical Center in Columbus, prescription for patients who were eligible for metabolic and bariatric surgery (MBS) for glucagon-like peptide-1 receptor agonist (GLP-1 RA) increased from 2018 to 2025, while MBS use decreased beginning in 2023. “To our knowledge, this is the first study to provide evidence that trends in MBS use have not yet stabilised through quarter 3 of 2025,” the researchers noted. “Stratification by

Wegovy may have highest ischaemic optic neuropathy and sight loss risk

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of ischaemic optic neuropathy (ION) and sudden sight loss of the semaglutide drugs, according to a study by researchers from the University of Ottawa, Ottawa, Ontario, Canada. They found that the risk is almost five times higher with Wegovy than it is with Ozempic, and three times greater in men than it is in women. ION is caused by inadequate/interrupted blood flow to the optic nerve, resulting in sudden vis

GLP-1 receptor agonist may increase long-term risks of osteoporosis

Research presented at the 2026 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) has found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may be associated with improved short-term postoperative benefits, alongside possible long-term risks of osteoporosis, gout and osteomalacia compared with non-users. “We are just now reaching the precipice where five- and 10-year follow-up data are becoming available for patients taking GLP-1 medications,” sa

First patient dosed in trial of SYNT-101 for obesity

The first patient has been dosed in Syntis Bio's the Phase 1/1b SYNTIETY-1 clinical trial of SYNT-101, the company’s lead investigational program for the treatment of obesity. SYNT-101 is designed as a once-daily oral pill that redirects nutrient absorption past the small intestine’s duodenum, mimicking the effects of gastric bypass surgery. SYNT-101 works by transiently blocking nutrient absorption in the duodenum, the upper part of the small intestine, and redirecting nutri

FDA approves Allurion Gastric Balloon System

The FDA has approved the premarket approval (PMA) application for the Allurion Gastric Balloon System (AGBS), featuring the Allurion Smart Capsule. The Allurion Program is a weight-loss platform that combines the FDA PMA approved Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, with the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers featuring the Iris AI platform, Allurion Insights for healthcare providers, and the Allurion

Industry

Olympus launches next-generation VISERA ELITE III surgical imaging platform in US

FDA approves Allurion Gastric Balloon System

Europe approves 7.2 mg injectable Wegovy for adults with obesity

FDA approves Novo Nordisk's oral GLP-1 for weight loss

All caught up?

See all news

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Browse directory

Events

14th Congress of the European Chapter of the International Federation for the Surgery and Other Therapies For Obesity

View details

1 September 2026

XXIX IFSO World Congress

View details

3 December 2025

8TH Gulf Obesity Surgery Society International Conference

View details

Headlines

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Bariatric surgery outperforms medical therapy for T2D across income levels

Research

Higher occurrence of marginal ulcers RYGB compared with OAGB

GLP-1 may help alleviate symptoms of anxiety and depression

IFSO ‘cautiously’ supports the selective use of ring augmentation in both primary and revisional MBS

Study identifies how obesity-related liver cancer becomes more aggressive and resistant to treatment

New genetic risk score better predicts metabolic conditions

Discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain

Olympus launches next-generation VISERA ELITE III surgical imaging platform in US

Rise in GLP-1 treatment for bariatric surgery-eligible patients

Wegovy may have highest ischaemic optic neuropathy and sight loss risk

GLP-1 receptor agonist may increase long-term risks of osteoporosis

First patient dosed in trial of SYNT-101 for obesity

FDA approves Allurion Gastric Balloon System

Industry

Olympus launches next-generation VISERA ELITE III surgical imaging platform in US

FDA approves Allurion Gastric Balloon System

Europe approves 7.2 mg injectable Wegovy for adults with obesity

FDA approves Novo Nordisk's oral GLP-1 for weight loss

All caught up?

New: Directory

Discover global suppliers of specialist bariatric services, treatments, products, and medical equipment.

Events

(See all)

4th IFSO MENAC Meeting

BOMSS ASM 2026

6th London International Bariatric Surgery Symposium (LIBSS)

2026 IBC University of Oxford World Congress

14th Congress of the European Chapter of the International Federation for the Surgery and Other Therapies For Obesity

XXIX IFSO World Congress

8TH Gulf Obesity Surgery Society International Conference

Tweets

Back to Top